P2‐029: RATIONALE AND DESIGN OF A PROSPECTIVE, RANDOMIZED, DOUBLE‐BLIND, DOSE‐COMPARISON SAFETY AND TOLERABILITY STUDY OF GRF6019 IN MILD‐TO‐MODERATE ALZHEIMER'S DISEASE. (1st July 2006)